Pancreatic Cancer Research

ResearcherChina Medical UniversityActive in the last 2 years

Ro‐Ting Lin

Matched on ORCID iD 0000-0002-2687-203X; OpenAlex author ID A5030994154. Sources: OpenAlex.

Their work

Papers
9 (first author 3, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
14
Papers, trials and grants by year

2022: 4 papers · 2023: 3 papers · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 9

  1. Association between a combined lifestyle exposure index and age at pancreatic cancer diagnosis: a hospital-based retrospective study. Last author DOI 10.1186/s12876-026-05297-0↗
  2. Dose-response relationship of cadmium and pancreatic cancer risk: a meta-analysis. Last author DOI 10.1136/oemed-2025-110163↗
  3. Association between residential exposure to petrochemical industrial complexes and pancreatic cancer: a systematic review and meta-analysis. First author DOI 10.1080/09603123.2021.2007226↗
  4. Duration-response association between occupational exposure and pancreatic cancer risk: meta-analysis. Last author DOI 10.1093/occmed/kqad050↗
  5. Diagnostic rate of germline pathogenic variants in pancreatic ductal adenocarcinoma patients using whole genome sequencing. First author DOI 10.3389/fgene.2023.1172365↗
  6. Accuracy of simultaneous measurement of serum biomarkers: Carbohydrate antigen 19-9, pancreatic elastase-1, amylase, and lipase for diagnosing pancreatic ducta… First author DOI 10.1016/j.jfma.2022.07.003↗
  7. Endoscopic ultrasound-guided fine-needle biopsy as a tool for studying the intra-tumoral microbiome in pancreatic ductal adenocarcinoma: a pilot study. Co-author DOI 10.1038/s41598-021-04095-w↗
  8. Risk factors related to age at diagnosis of pancreatic cancer: a retrospective cohort pilot study. Co-author DOI 10.1186/s12876-022-02325-7↗
  9. "Sugar-Sweetened Beverages" Is an Independent Risk From Pancreatic Cancer: Based on Half a Million Asian Cohort Followed for 25 Years. Co-author DOI 10.3389/fonc.2022.835901↗

Closest collaborators

The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jaw-Town Lin · 4 shared papers, 2022–2026 · strength 0.91
  2. Fu‐Jen Lee · 2 shared papers, 2025–2026 · strength 0.72
  3. Chi‐Ying Yang · 4 shared papers, 2022–2023 · strength 0.68
  4. Hathaichon Boonhat · 2 shared papers, 2023 · strength 0.57
  5. Jaw‐Town Lin · 2 shared papers, 2022–2023 · strength 0.46
  6. An‐Ko Chung · 2 shared papers, 2022–2023 · strength 0.37
  7. Jaw‐Town Lin · 1 shared paper, 2025 · strength 0.33
  8. Chia‐Sheng Chu · 2 shared papers, 2022 · strength 0.31
  9. Xifeng Wu · 1 shared paper, 2022 · strength 0.16
  10. Chi Pang Wen · 1 shared paper, 2022 · strength 0.16
  11. Chien‐Hua Chen · 1 shared paper, 2022 · strength 0.16
  12. Chao‐Ming Tseng · 1 shared paper, 2022 · strength 0.16
  13. Li‐Yuan Bai · 1 shared paper, 2022 · strength 0.15
  14. Mien‐Chie Hung · 1 shared paper, 2022 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.